Global Nucleic Acid Isolation and Purification Market Size, Forecast, and Trend Highlights Over 2025-2037
Nucleic Acid Isolation and Purification Market size was valued at USD 8.6 billion in 2024 and is projected to reach USD 24.9 billion by the end of 2037, rising at a CAGR of 10.2% during the forecast period, i.e., 2025 to 2037. In 2025, the industry size is expected to be USD 9.2 billion.
The global nucleic acid isolation and purification market is gaining traction, fueled by the increasing demand for advanced diagnostics, next-generation sequencing, and wider applications in gene therapy. Besides, the market has a large consumer base in terms of cancer, infectious disease, and genetic disorder patients. In this context NIH report in 2023 states that more than 58 million genetic tests were performed in the U.S., reflecting the growing adoption of high-throughput nucleic acid extraction systems. Additionally, the USITC in 2024 notified that the imports of nucleic acid extraction kits increased by 18% from 2023, mainly from Germany and Japan, similarly, the exports of associated equipment are led by the U.S., which increased by 12%.
Furthermore, the growth in the market is significantly influenced by global supply chain activities and funding initiatives from both private and public sectors. In this regard, NIH in 2024 reported that it allocated USD 2.0 billion for genomic medicine and nucleic acid extraction technologies. Furthermore, the producer price index and consumer price index are enhanced, which rose by 4.5% and 5.3% owing to the higher downstream costs reported by the Bureau of Labor Statistics in 2024. Therefore, this is the evidence for a wider scope of nucleic acid isolation and purification market expansion during the forecast timeline.
Nucleic Acid Isolation and Purification Sector: Growth Drivers and Challenges
Growth Drivers
-
Increasing burden of chronic diseases: One of the major contributors to the nucleic acid isolation and purification market is the rising burden of chronic diseases such as cancer, genetic disorders, and infectious diseases. This, in turn, necessitates the requirement for nucleic acid testing. In this regard CDC report in 2024 reported more than 2.1 million cases of cancer require biomarker testing that fuels the demand for isolation kits. Besides, as there is a 12% increase in rare genetic disorders in Europe, the reliance on PCR and NGS-based purification increases further, reflecting a positive market adoption.
- Personalized medicine expansion: There is a heightened usage of gene therapies and personalized medicine in the vast healthcare sector. In this regard, the U.S. FDA in 2024 states that its approval for more than 10 gene therapies requires ultra-pure DNA or RNA isolation. Besides, the NHS in 2023 notifies that a clinical study in the U.K. found that these personalized cancer treatments remarkably increased the demand for extraction kit by more than 35% thus readily augmenting market expansion.
Manufacturer Strategies Shaping Nucleic Acid Isolation and Purification Market Expansion
There is a huge opportunity for manufacturers involved in the market who are putting constant efforts to strengthen their global ecosystem. Key trends figured by the players include automation, collaborations, and a substantial increase in domestic production. For instance, in 2023, Thermo Fisher Scientific announced the launch of KingFisher Revv, which increased its revenue by USD 225 million. Besides WHO report in 2024 states that the future growth in the market extensively relies on affordable solutions in the developing nations, where more than 50% of labs are still leveraging manual methods.
Revenue Opportunities for Manufacturers (2023–2024)
|
Company |
Strategy |
Revenue Impact |
|
Thermo Fisher |
KingFisher Revv launch |
+$225 million |
|
Qiagen |
NIH partnership for LMIC kits |
10% market share gain |
|
Roche |
U.S. reagent production |
$160 million CDC contracts |
|
Illumina |
FDA-cleared RNA extraction automation |
+$182 million |
|
Bio-Rad |
Point-of-care kit expansion |
+14% YoY growth |
Feasible Expansion Models Shaping the Nucleic Acid Isolation and Purification Market
The global nucleic acid isolation and purification market is witnessing expansion shaped by various feasibility models such as partnerships with domestic firms, strategic pricing, and offering automation as a service. In this regard, it is reported that Tata Medical partnered with Illumina, intending to offer affordable extraction systems that increased revenue by 14% from 2022 to 2024. Furthermore, the CDC invested USD 55 million in decentralized testing hubs that substantially expanded access to automated extraction in the rural clinics of the U.S. Hence, these models are anticipated to readily blister the market progression during the forecast timeline.
Feasibility Models for Market Expansion
|
Region |
Model |
Outcome |
|
India |
PPP with Illumina |
+14% revenue (2022–2024) |
|
USA |
CDC-funded automation hubs |
20% cost reduction |
|
Brazil |
Fiocruz bead-tech scaling |
26% lower imports |
Challenge
-
Cost limitations in developing nations: This is one of the major restraints in the nucleic acid isolation and purification market that hinders adoption in price-sensitive regions. WHO states that above 78% of labs in Africa witness funding shortages, due to which they can’t afford 5 test kits. To mitigate this, Bio-Rad offered a kit for USD 1.5 that gained a 16% increased share in Kenya. Besides, the funding subsidies are offering only 28%, which diminishes the industry adoption among people belonging to low-income nations.
Nucleic Acid Isolation and Purification Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
10.2% |
|
Base Year Market Size (2024) |
USD 8.6 billion |
|
Forecast Year Market Size (2037) |
USD 24.9 billion |
|
Regional Scope |
|
Nucleic Acid Isolation & Purification Segmentation
Product (Kits & Reagents, Instruments, Automated Systems)
Based on product, the kits & reagents segment is expected to garner the highest share of 62.7% in the nucleic acid isolation and purification market by the end of 2037. The dominance of the segment is attributed to the growing demand for affordable solutions in healthcare facilities. Moreover, the products are the ideal choice for various applications such as gene sequencing, diagnostics, and molecular biology research. In this regard, WHO reports 355 million annual viral hepatitis tests, mostly using RNA extraction kits, an augmentation of innovation in extraction kits, further accelerating the segment’s dominance.
Application (Diagnostics, Drug Discovery, Genomics, Agriculture)
Based on the application, the diagnostics segment is projected to account for a lucrative share of 48.9% in the nucleic acid isolation and purification market during the forecast period. The growth in the segment is subject to increased applications of DNA and RNA isolation for the identification of pathogens in routine sample processing. Besides, the Medicare expenditure for companion diagnostics associated with nucleic acid purification increased by 25%, i.e., USD 900 million in 2023, further contributing to the dominance of the segment. Additionally, the occurrence of COVID-19 remarkably increased the demand for innovative diagnostic tools.
Our in-depth analysis of the nucleic acid isolation and purification market includes the following segments:
|
Product |
|
|
Application |
|
|
Method |
|
|
End Use |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportNucleic Acid Isolation & Purification Industry– Regional Synopsis
North America Market Analysis
The North America nucleic acid isolation and purification market is poised to capture the largest share of 35.9% during the forecast period, rising at a CAGR of 8.4%. The region is witnessing such growth driven by factors such as increasing investments in research and development, robust medical infrastructure, and funding from federal groups. Besides, in 2022 Department of Energy allocated a significant amount of USD 180 million in support of biotechnology and biomanufacturing research, reflecting a positive market support. The rising number of infectious disease testing further propels market expansion in the region.
The Canada nucleic acid isolation and purification market is witnessing robust growth opportunities fueled by expanded healthcare budgets and industry collaboration. In this context, in 2023, Canada enhanced its federal healthcare budget with a 13% increase from 2020, which is 9% of its budget, with a substantial USD 3.3 billion. Similarly, the provincial healthcare investments increased by 20% from 2021 to 2024, benefiting more than 200,000 patients in a year. This growing prominence of the country in this sector is driving business in nucleic acid isolation and purification further.
Asia Pacific Market Statistics
Asia Pacific nucleic acid isolation and purification market is unfolding remarkable growth opportunities with the fastest growth and a lucrative share of 25.6%, rising at a CAGR of 9.2% during the forecast timeline. The growth in the region is majorly fueled by the presence of key countries such as India, China, Japan, and South Korea, and their developmental superiority. Besides, the region’s governments offer their extended support with substantial investments and advanced diagnostic technologies that propel market growth, positioning Asia Pacific as a key leader in the market.
China is a global leader in the nucleic acid isolation and purification market, driven by the extensive support from public healthcare systems. In this context, government expenditure for nucleic acid isolation and purification increased by 18% over the last five years, demonstrating the country’s focus on molecular and biotechnology diagnostics. Besides, it is reported that in 2023, more than 1.6 million individuals diagnosed their conditions with nucleic acid-based methods, reflecting their higher accuracy and adoption. NMPA approved above 45 NGS kits, with the push towards precision medicine, thus denoting a positive market outlook.
Companies Dominating the Nucleic Acid Isolation and Purification Landscape
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The companies involved in the nucleic acid isolation and purification market are emphasizing numerous tactical strategies to strengthen their position in the global market landscape. The market is highly consolidated with intensifying competition between the key players. Companies such as Thermo Fisher, Qiagen, and Roche are dominating with a huge 52% of the global share. Besides this, leading firms are undertaking specifications such as automation, expansion in developing nations, and NGS integration to enhance their workflow. Furthermore, mergers and acquisitions, along with supportive regulatory frameworks, also boost healthy competition among the players.
Below is the list of a few prominent players in the industry:
|
Company Name |
Country |
Market Share |
|
Thermo Fisher Scientific |
USA |
23% |
|
Qiagen |
Germany |
20% |
|
Roche Diagnostics |
Switzerland |
14% |
|
Illumina |
USA |
10% |
|
Danaher |
USA |
9% |
|
Agilent Technologies |
USA |
xx% |
|
Merck KGaA |
Germany |
xx% |
|
Bio-Rad Laboratories |
USA |
xx% |
|
Takara Bio |
Japan |
xx% |
|
BGI Genomics |
China |
xx% |
|
Promega |
USA |
xx% |
|
New England Biolabs |
USA |
xx% |
|
F. Hoffmann-La Roche |
Switzerland |
xx% |
|
PerkinElmer |
USA |
xx% |
|
LGC Biosearch Technologies |
UK |
xx% |
|
Macherey-Nagel |
Germany |
xx% |
|
Zymo Research |
USA |
xx% |
|
BioMerieux |
France |
xx% |
|
Seegene |
South Korea |
xx% |
|
Medigen Biotech |
Taiwan |
xx% |
Below are the areas covered for each company under the top 15 global manufacturers:
Recent Developments
- In March 2024, Thermo Fisher Scientific launched the KingFisher Pure NA Isolation System, which is a high-throughput, automated NAIP platform for clinical and research labs. Designed to process 1,000+ samples per day with less than 5% contamination risk.
- In January 2024, Qiagen launched QIAcube Connect MDx which is an FDA-cleared NAIP system for diagnostics, integrating AI for error reduction that targets oncology and infectious disease testing.
Author Credits: Radhika Pawar
- Report ID: 2630
- Published Date: Jun 02, 2025
- Report Format: PDF, PPT
